A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Phase 1

• Conditions: Relapsed or Refractory Multiple Myeloma
• Interventions: Biological: C-CAR088

• Registration Number: NCT03815383
• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Brief Summary

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

Detailed Description

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Study Timeline

• Status Verified: 2018-12
• Study First Submitted: 2019-01-22
• Study First Submitted QC: 2019-01-22
• Study First Posted: 2019-01-24
• Study Start: 2019-04-11
• Last Update Submitted: 2019-07-01
• Last Update Posted: 2019-07-05
• Primary Completion: 2021-01
• Study Completion: 2021-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Volunteered to participate in this study and signed informed consent.

2. Age 18-75 years old, male or female.

3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014).

4. Patients with relapsed or refractory multiple myeloma.

5. Subjects have one or more measurable multiple myeloma lesion, must include one of the following conditions:

   • Serum M protein≥1 g/dl(10g/L)
   • Urine M protein≥200 mg/24h
   • Serum free light chain(sFLC): κ/λ ratio abnormal and ≥10 mg/dl

6. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.

7. At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy.

8. ECOG scores 0 - 1.

9. Normal cardiac diastolic function, left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography), no serious arrhythmia.

10. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.

11. No contraindications of leukapheresis.

12. Expected survival > 12 weeks.

13. Female subjects in childbearing age, their serum or urine pregnancy test must be negative,until 7 days before cell therapy and all subjects must agree to take effective contraceptive measures during the trial.

Exclusion Criteria

1. Have a history of allergy to cellular products.
2. Any kind of these laboratory testing: including but not limited to,serum total bilirubin≧1.5mg/dl, serum ALT, AST≧2.5×ULN, serum creatinine≧2.0mg/dl, Hb (hemoglobin)<80g/L, neutrophils<1000/mm^3, platelets≦50000/mm^3 or platelet count maintained by transfusion.
3. Subjects with the clinically significant cardiovascular diseases.
4. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease.
5. Use any anticoagulant (except aspirin).
6. Patients requiring urgent treatment due to tumor progression or spinal cord compression.
7. Patients with active CNS involvement or clinical syndrome of MM meningeal involvement.
8. After allogeneic hematopoietic stem cell transplantation.
9. Plasma cell leukemia.
10. Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy.
11. Uncontrolled active infection.
12. Prior treatment with CAR T therapy or any other genetically modified T cell therapy.
13. Live vaccine inoculation within four weeks before enrollment.
14. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons.
15. Have a history of alcoholism, drug addiction and mental illness.
16. Participated in any other clinical trial within one month.
17. The investigators believe that there are other circumstances that are not suitable for the trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
C-CAR088	C-CAR088	Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene

Primary Outcome Measures

Name	Time	Method
Safety:TEAEs	30 days	The incidence of treatment-emergent adverse events (TEAEs)

Secondary Outcome Measures

Name	Time	Method
ORR	12 months	Overall response rate
PFS	6 months, 12 months	Progression free survival

Trial Locations

Locations (1)

the First Affiliated Hospital of Nanjing Medical University; 🇨🇳 Nanjing, Jiangsu, China